Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Scoparone (6,7-dimethoxycoumarin) is a natural bioactive coumarin derivative primarily isolated from the stems and leaves of *Artemisia capillaris*. It exhibits a broad spectrum of pharmacological activities, including anti-inflammatory, anti-oxidant, anti-tumor, lipid-lowering, and anti-coagulant effects. In oncology research, particularly concerning breast cancer, scoparone has been shown to inhibit cell viability and migration while promoting apoptosis. Its mechanism of action involves the suppression of the NF-κB signaling pathway, which is achieved through the regulation of the SNHG12/miR-140-3p/TRAF2 axis. Specifically, scoparone inhibits the expression of the long non-coding RNA SNHG12, leading to the upregulation of miR-140-3p and the subsequent downregulation of TRAF2. Historically, scoparone has also been recognized for its hypotensive and cholagogic (bile-promoting) properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scoparone.